



# Pharmaceuticals – Pipeline Overview<sup>1</sup> (as of December 11, 2024)

Phase I	Phase II	Phase III
<b>HER2/mEGFR Inhibitor</b> (BAY 2927088)	<b>Congestive Heart Failure rAAV Gene Therapy</b> (AB-1002)	<b>Darolutamide</b> (AR Inhibitor)
<b>DGKzeta Inhibitor</b> (BAY 2965501)	<b>Anti-α2AP</b> (BAY 3018250)	<b>HER2/mEGFR Inhibitor</b>
<b>Lanerkitug</b> (CCR8 Ab) (BAY 3375968)	<b>Nurandociguat</b> (sGC Activator Oral) (BAY 3283142)	<b>Finerenone</b> (MR Antagonist)
<b>VVD KEAP1 Act</b> (VVD-130037 aka NRF2 Inh, BAY 3605349)	<b>Parkinson's Disease rAAV Gene Therapy</b> (AB-1005)	<b>Vericiguat</b> (sGC Stimulator)
<b>DGKalpha Inh</b> (BAY 2862789)		<b>Asundexian</b> (FXIa Inhibitor)
<b>225Ac-Pelgifatamab</b> (BAY 3546828)		<b>Aflibercept 8mg</b> (VEGF Inhibitor)
<b>VVD STAT3 Inhibitor</b> (VVD-130850, BAY 3630914)		<b>Gadoquatrane</b> (High Relaxivity Contrast Agent)
<b>225Ac-PSMA-Trillium</b> (BAY 3563254)		
<b>SOS1 Inhibitor</b> (BAY 3498264)		
<b>SEMA 3a</b> (BAY 3401016)		
<b>Anti-coagulant</b> (BAY 3389934)		
<b>Bemdaneprocel</b> (Parkinson's Disease Cell Therapy) (BRT-DA01)		
<b>Multiple System Atrophy rAAV Gene Therapy</b> (AB-1005 aka AAV2-GDNF-MSA)		
<b>Pompe Disease rAAV Gene Therapy</b> (ACTUS-101)		
<b>LGMD2I/R9 rAAV Gene Therapy</b> (AB-1003 aka LION-101)		
<b>GPR84 Antagonist</b> (BAY 3178275)		
<b>BAY 2701250</b>		
		<b>Submissions</b>
		<b>Darolutamide</b> (AR Inhibitor)
		<b>Elinzanetant</b> (Neurokinin-1,3 Rec Antagonist)
		<b>Aflibercept 8mg</b> (VEGF-Inhibitor)
		<b>Acoramidis<sup>4</sup></b> (TTR-Stabilizer)

- Oncology
- Cardiovascular+<sup>3</sup>
- Neurology & Rare Diseases
- Immunology
- Others

- New molecular entity
- Life cycle management

- Protein Therapeutics
- Cell Therapy
- Contrast Agent
- Genetic Medicine
- Radionuclide Therapy
- Small Molecule

<sup>1</sup> Bayer and partner sponsored + 3rd party label enabling studies with first patient first visit  
<sup>2</sup> Conducted by Merck & Co <sup>3</sup> Including Precision Cardiovascular, Nephrology & Acute Care  
<sup>4</sup> Exclusive commercialization rights acquired for EU markets; pending marketing authorization approval. Submission to EMA under responsibility of BridgeBio